• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Friday's After-Market Session

    12/30/22 4:33:40 PM ET
    $ADAP
    $ALR
    $BNTC
    $BXRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Hospital/Nursing Management
    Health Care
    Get the next $ADAP alert in real time by email

    Gainers

    • Invacare (NYSE:IVC) stock rose 14.3% to $0.48 during Friday's after-market session. The market value of their outstanding shares is at $18.1 million.
    • Benitec Biopharma (NASDAQ:BNTC) stock increased by 11.7% to $0.19. The market value of their outstanding shares is at $5.3 million.
    • AlerisLife (NASDAQ:ALR) stock moved upwards by 9.09% to $0.6. The company's market cap stands at $19.5 million.
    • Renalytix (NASDAQ:RNLX) shares rose 8.55% to $2.03. The company's market cap stands at $76.0 million.
    • electroCore (NASDAQ:ECOR) shares increased by 8.52% to $0.28. The market value of their outstanding shares is at $19.8 million.
    • Statera BioPharma (NASDAQ:STAB) stock increased by 8.37% to $0.09. The company's market cap stands at $4.8 million.

    Losers

    • Salarius Pharmaceuticals (NASDAQ:SLRX) shares declined by 13.7% to $1.32 during Friday's after-market session. The company's market cap stands at $3.0 million.
    • GreenLight Biosciences (NASDAQ:GRNA) stock declined by 10.17% to $1.06. The company's market cap stands at $160.6 million.
    • Intelligent Bio Solutions (NASDAQ:INBS) stock decreased by 8.91% to $0.18. The market value of their outstanding shares is at $3.3 million.
    • Baudax Bio (NASDAQ:BXRX) stock declined by 8.5% to $2.91. Trading volume for this security closed at 518.1K, accounting for 46.0% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $1.6 million.
    • Finch Therapeutics Group (NASDAQ:FNCH) shares decreased by 8.32% to $0.44. The market value of their outstanding shares is at $21.0 million.
    • Adaptimmune Therapeutics (NASDAQ:ADAP) stock declined by 7.54% to $1.35. The company's market cap stands at $221.1 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ADAP alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADAP
    $ALR
    $BNTC
    $BXRX

    CompanyDatePrice TargetRatingAnalyst
    Adaptimmune Therapeutics plc
    $ADAP
    7/29/2025Buy → Neutral
    H.C. Wainwright
    Benitec Biopharma Inc.
    $BNTC
    7/7/2025Buy
    TD Cowen
    Adaptimmune Therapeutics plc
    $ADAP
    6/26/2025$0.50Outperform → Neutral
    Mizuho
    Benitec Biopharma Inc.
    $BNTC
    12/16/2024$28.00Buy
    H.C. Wainwright
    Benitec Biopharma Inc.
    $BNTC
    12/13/2024$30.00Outperform
    Robert W. Baird
    Benitec Biopharma Inc.
    $BNTC
    10/16/2024$35.00Outperform
    Oppenheimer
    Benitec Biopharma Inc.
    $BNTC
    9/12/2024$17.00Buy
    Guggenheim
    Adaptimmune Therapeutics plc
    $ADAP
    7/30/2024$4.00Buy
    H.C. Wainwright
    More analyst ratings

    $ADAP
    $ALR
    $BNTC
    $BXRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Adaptimmune Therapeutics downgraded by H.C. Wainwright

    H.C. Wainwright downgraded Adaptimmune Therapeutics from Buy to Neutral

    7/29/25 7:36:15 AM ET
    $ADAP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    TD Cowen initiated coverage on Benitec Biopharma

    TD Cowen initiated coverage of Benitec Biopharma with a rating of Buy

    7/7/25 8:17:08 AM ET
    $BNTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Adaptimmune Therapeutics downgraded by Mizuho with a new price target

    Mizuho downgraded Adaptimmune Therapeutics from Outperform to Neutral and set a new price target of $0.50

    6/26/25 7:50:31 AM ET
    $ADAP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADAP
    $ALR
    $BNTC
    $BXRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Errico Thomas J.

    4 - electroCore, Inc. (0001560258) (Issuer)

    3/20/26 6:01:50 AM ET
    $ECOR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Chief Executive Officer Goldberger Daniel S was granted 46,375 shares, increasing direct ownership by 16% to 338,940 units (SEC Form 4)

    4 - electroCore, Inc. (0001560258) (Issuer)

    1/28/26 4:30:05 PM ET
    $ECOR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Chief Financial Officer Lev Joshua S. was granted 27,889 shares, increasing direct ownership by 129% to 49,556 units (SEC Form 4)

    4 - electroCore, Inc. (0001560258) (Issuer)

    1/28/26 4:30:06 PM ET
    $ECOR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ADAP
    $ALR
    $BNTC
    $BXRX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    electroCore Announces Full Year 2025 Financial Results and Organizational Changes

    Record full year 2025 net sales of $32.0, an increase of 27% over $25.2 million for the full year 2024 driven by 25% annual growth in our U.S. prescription business and 97% increase in general wellness sales Announces the retirement of Dan Goldberger as Chief Executive Officer in addition to other key executive management changes Company to host a conference call and webcast today, March 19, 2026, at 4:30pm EDT ROCKAWAY, N.J., March 19, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR) ("electroCore" or the "Company"), a bioelectronic technology company, today announced full year 2025 financial results. Reported record full year of 2025 revenue of $32.0 million, an increase of a

    3/19/26 4:05:00 PM ET
    $ECOR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    electroCore to Participate at the 38th Annual Roth Conference

    ROCKAWAY, N.J., March 10, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a bioelectronic medicine and wellness company, announced today that management will participate in the 38th Annual Roth Conference March 22-24 at the Ritz-Carlton in Laguna Niguel, California. Joshua Lev, Chief Financial Officer, will host one-on-one meetings at the conference. Investors attending this event who are interested in scheduling a meeting with management can do so by contacting their respective Roth representative, or by emailing [email protected] for more information. About the Roth Capital Partners ConferenceThe Annual ROTH Conference is one of the largest in the nation for small-cap

    3/10/26 8:00:00 AM ET
    $ECOR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Benitec Biopharma to Host Industry Forum Breakfast Event at the 2026 Muscular Dystrophy Association Clinical and Scientific Conference on March 10, 2026, Highlighting Continued Progress for BB-301, the Only Clinical-Stage Therapeutic in Development for Oculopharyngeal Muscular Dystrophy (OPMD)

    HAYWARD, Calif., March 10, 2026 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary "Silence and Replace" DNA-directed RNA interference ("ddRNAi") platform, is hosting an Industry Forum Breakfast and presentation on Tuesday, March 10, at the 2026 Muscular Dystrophy Association (MDA) Clinical and Scientific Conference. The presentation will highlight the key clinical results observed to date for OPMD Patients enrolled into the BB-301 Phase 1b/2a Clinical Treatment Study (NCT06185673) and the potential for BB-301 to transform the treatment l

    3/10/26 7:00:00 AM ET
    $BNTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADAP
    $ALR
    $BNTC
    $BXRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Suvretta Capital Management, Llc bought $1,903,133 worth of shares (144,223 units at $13.20) (SEC Form 4)

    4 - Benitec Biopharma Inc. (0001808898) (Issuer)

    12/29/25 7:31:28 PM ET
    $BNTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Suvretta Capital Management, Llc bought $538,972 worth of shares (46,141 units at $11.68) (SEC Form 4)

    4 - Benitec Biopharma Inc. (0001808898) (Issuer)

    12/22/25 7:45:03 PM ET
    $BNTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Goldberger Daniel S bought $4,840 worth of shares (1,000 units at $4.84), increasing direct ownership by 0.34% to 292,565 units (SEC Form 4)

    4 - electroCore, Inc. (0001560258) (Issuer)

    12/3/25 7:00:20 AM ET
    $ECOR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ADAP
    $ALR
    $BNTC
    $BXRX
    SEC Filings

    View All

    Amendment: SEC Form 10-K/A filed by Benitec Biopharma Inc.

    10-K/A - Benitec Biopharma Inc. (0001808898) (Filer)

    3/20/26 4:03:01 PM ET
    $BNTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by electroCore Inc.

    S-8 - electroCore, Inc. (0001560258) (Filer)

    3/19/26 5:22:57 PM ET
    $ECOR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 10-K filed by electroCore Inc.

    10-K - electroCore, Inc. (0001560258) (Filer)

    3/19/26 4:35:29 PM ET
    $ECOR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ADAP
    $ALR
    $BNTC
    $BXRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Benitec Biopharma Inc.

    SC 13G/A - Benitec Biopharma Inc. (0001808898) (Subject)

    12/6/24 1:47:28 PM ET
    $BNTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Benitec Biopharma Inc.

    SC 13D/A - Benitec Biopharma Inc. (0001808898) (Subject)

    11/18/24 4:36:00 PM ET
    $BNTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Salarius Pharmaceuticals Inc.

    SC 13G/A - Salarius Pharmaceuticals, Inc. (0001615219) (Subject)

    11/14/24 4:38:31 PM ET
    $SLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADAP
    $ALR
    $BNTC
    $BXRX
    Financials

    Live finance-specific insights

    View All

    electroCore Announces Full Year 2025 Financial Results and Organizational Changes

    Record full year 2025 net sales of $32.0, an increase of 27% over $25.2 million for the full year 2024 driven by 25% annual growth in our U.S. prescription business and 97% increase in general wellness sales Announces the retirement of Dan Goldberger as Chief Executive Officer in addition to other key executive management changes Company to host a conference call and webcast today, March 19, 2026, at 4:30pm EDT ROCKAWAY, N.J., March 19, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR) ("electroCore" or the "Company"), a bioelectronic technology company, today announced full year 2025 financial results. Reported record full year of 2025 revenue of $32.0 million, an increase of a

    3/19/26 4:05:00 PM ET
    $ECOR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    electroCore Announces Third Quarter 2025 Financial Results

    Net sales of $8.7 million increased 33% vs. Q3 2024; YTD net sales of $22.8 million increased 26% vs. first nine months of 2024 Cash, cash equivalents, restricted cash, and marketable securities ("Total Cash") of $13.2 million as of September 30, 2025  Company to host a conference call and webcast today, November 5, 2025, at 4:30 p.m. EDT ROCKAWAY, N.J., Nov. 05, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR) ("electroCore" or the "Company"), a bioelectronic technology company, today announced financial results for the three and nine months ended September 30, 2025. Recent Highlights Record revenue for Q3 2025 of $8.7 million, a 33% increase over Q3'2024Year-to-date revenue

    11/5/25 4:05:00 PM ET
    $ECOR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Benitec Biopharma Releases Full Year 2025 Financial Results and Provides Operational Update

    Interim Clinical Study Results for Cohort 1 of the BB-301 Phase 1b/2a Treatment Study Anticipated in Q4 2025 Enrollment of the First Subject into Cohort 2 of the BB-301 Phase 1b/2a Treatment Study Expected in Q4 2025 HAYWARD, Calif., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary "Silence and Replace" DNA-directed RNA interference ("ddRNAi") platform, today announced financial results for its full year ended June 30, 2025. The Company has filed its annual report on Form 10-K with the U.S. Securities and Exchange Commi

    9/22/25 4:05:00 PM ET
    $BNTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADAP
    $ALR
    $BNTC
    $BXRX
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    Stock Movement: Insider Purchase at electroCore Inc. on Jun 6

    **Analysis of Recent Insider Purchase at electroCore Inc.** An insider purchase was recently made at electroCore Inc. by Goldberger Daniel S on June 6, 2024. This transaction involved the purchase of $247,587 worth of shares, equating to 38,505 units at an average price of $6.43 per share. As a result of this purchase, Goldberger's direct ownership in the company increased by 18% to 249,565 units, as reported in the SEC Form 4 filing. Looking at the historical insider transactions at electroCore Inc., several interesting patterns emerge when analyzing the timing, price, volume, purchaser's role, and more. On August 8, 2023, Goldstein Julie Ann and Cuneo F Peter both filed SEC Form 4 report

    6/10/24 12:57:57 AM ET
    $ECOR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ADAP
    $ALR
    $BNTC
    $BXRX
    Leadership Updates

    Live Leadership Updates

    View All

    Benitec Biopharma Announces Appointment of Sharon Mates Ph.D. to its Board of Directors

    HAYWARD, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary "Silence and Replace" DNA-directed RNA interference ("ddRNAi") platform, today announces the appointment of Dr. Sharon Mates to the board of directors (BOD) of the Company, effective November 2, 2025. "We are delighted to welcome Dr. Sharon Mates to Benitec's Board of Directors," said Jerel Banks, M.D., Ph.D., Chairman and Chief Executive Officer of Benitec Biopharma. "Dr. Mates brings exceptional leadership experience in building successful biotechnology c

    11/3/25 7:00:00 AM ET
    $BNTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    electroCore Appoints Elena Bonfiglioli to Board of Directors

    ROCKAWAY, N.J., Sept. 03, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that Elena Bonfiglioli, an accomplished healthcare executive, has been appointed to electroCore's Board of Directors, effective September 2, 2025. Ms. Bonfiglioli's appointment follows the retirement from the Board of Peter Cuneo. Ms. Bonfiglioli has been working in the health sector for more than two decades. She currently serves as Microsoft's Global Business Leader for Healthcare, Pharma Life Sciences, and the International clinical applications' solutions, responsible for go-to-market, commercial, and partnerships, enabling

    9/3/25 8:00:00 AM ET
    $ECOR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    ANDMORE Establishes New Executive Team to Support Growth Plan

    Robert Klein Appointed Chief Financial Officer; Brings Extensive Financial and Real Estate Expertise Entirely New Executive Team Installed Under Jon Pertchik Leadership Leadership Changes Will Support Growth Plan to Improve Operations for the Category Leader ANDMORE®, the largest owner and operator of tradeshows in the U.S., today announced the appointment of Robert Klein as Chief Financial Officer. Klein joins ANDMORE from Postal Realty Trust, Inc. (NYSE:PSTL), where he served as Chief Financial Officer since 2021. "Nothing transforms a company more than excellent senior leadership, with diverse skillsets and broad-based experience," said Jonathan Pertchik, CEO of ANDMORE. "Our lea

    8/6/25 7:30:00 AM ET
    $PSTL
    $RMR
    $ALR
    Real Estate Investment Trusts
    Real Estate
    Professional Services
    Consumer Discretionary